Oral Etoposide for Ewing Sarcoma in Teens and Adults
Author Information
Author(s): Louise Kostos, Victoria Rayson, Jayesh Desai, Lisa Orme, Susie Bae, Anne Hamilton, Stephen J. Luen, Jeremy Lewin
Primary Institution: Peter MacCallum Cancer Centre
Hypothesis
Oral etoposide may provide antitumor activity in adult patients with relapsed or refractory Ewing sarcoma.
Conclusion
Oral etoposide showed some effectiveness and manageable side effects in treating adult patients with relapsed or refractory Ewing sarcoma.
Supporting Evidence
- Nine patients (27%) had stable disease for at least 6 months.
- Six patients (18%) had a partial response.
- The clinical benefit rate was 45%.
- The median progression-free survival was 3.6 months.
- The median overall survival was 8.5 months.
Takeaway
This study looked at how a medicine called oral etoposide helps older kids and adults with a type of cancer called Ewing sarcoma that comes back after treatment. It found that it can help some people feel better for a while.
Methodology
A retrospective analysis of 33 patients treated with oral etoposide at the Peter MacCallum Cancer Centre from 2005 to 2020.
Potential Biases
Potential biases due to the retrospective nature and lack of randomization.
Limitations
The study is retrospective, lacks a control group, and had incomplete data for some patients.
Participant Demographics
Median age at diagnosis was 21 years, with 70% of patients relapsing within 2 years of initial diagnosis.
Statistical Information
P-Value
0.012
Confidence Interval
95% CI: 1.7–5.5 for PFS; 95% CI: 4.1–13.0 for OS
Statistical Significance
p=0.012
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website